We also found that SMYD2 inhibitor (LLY‐507) showed similar growth‐suppressive effects in four NSCLC cell lines harboring TP53 mutations but not harboring either EML4‐ALK fused proteins or genetic defects in the APC‐β‐catenin pathway. This evidence concerns the gene SMYD2 and non-small cell lung carcinoma.